Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...

Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...

The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is ...

It is unknown if Tezspire (tezepelumab-ekko) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...

Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.